Company intelligence / Profile preview

Pulmoquine Therapeutics, Inc.

San Diego, California / Delaware filing origin, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Pulmoquine Therapeutics developed an inhaled formulation of hydroxychloroquine sulfate and completed a Phase 1 clinical trial evaluating its safety and pharmacokinetics in healthy adults. The study was conducted at Rockefeller University from June to October 2020. There are no reported further clinical results or ongoing programs; the company has since been dissolved.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Small molecules (hydroxychloroquine sulfate)
Industry: Biotech

Drug pipeline

1 asset

hydroxychloroquine

Phase 1

Indications: COVID-19

Partnerships

No major pharmaceutical or biotech partnerships identified.

Beyond the preview

Go deeper on Pulmoquine Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmoquine Therapeutics, Inc..

Explore the full profile